Medicaid Reimbursement for Vagus Nerve Stimulation

Beginning July 1, 2025 No later than January 1, 2026, the bill requires the department of health care policy and financing (HCPF) to seek federal authorization to reimburse acute care hospitals and ambulatory surgery facilities that provide vagus nerve stimulation therapy to members diagnosed with drug-resistant epilepsy at a rate that is equal to 75% 60% of the cost for acquiring the vagus nerve stimulator device, which reimbursement is in addition to and does not supplant the reimbursement for any necessary surgical procedure associated with implanting the device. Beginning January 1, 2029, the bill requires HCPF to increase the reimbursement to a rate that is equal to 75% of the cost for acquiring the vagus nerve simulator device. (Note: Italicized words indicate new material added to the original summary; dashes through words indicate deletions from the original summary.) (Note: This summary applies to the reengrossed version of this bill as introduced in the second house.)